|
|
<section data-role="paragraph" data-color="rgb(182, 228, 253)" data-custom="rgb(182, 228, 253)"><section data-role="paragraph" data-color="rgb(182, 228, 253)" data-custom="rgb(182, 228, 253)"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section><p><p><img src="image/20201014/86b79d371e9862b01189f0252a03b2cd_1.png" /></p></p></section><section><section><span><strong></strong></span></section><p><span>医疗器械媒体报道先锋</span></p><p><span>分享专业医疗器械知识</span></p></section><section><section><section>关注</section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><section><br /></section></section><section><section><section><p><img src="image/20201014/364db6caad85d46a1540a75d358c288e_2.jpg" /></p></section></section></section><p><strong><span>来源：</span></strong></p><p><strong><span><br /></span></strong></p><section><section powered-by="gulangu"><section><section><p>诺华公司 （纽约证券交易所股票代码：NVS）子公司 爱尔康于3月18日宣布，它以2.85亿美元收购了人工晶状体开发商PowerVision。</p></section></section></section><section powered-by="gulangu"><section><section><p><br /></p></section></section></section><section powered-by="gulangu"><section><section><section powered-by="gulangu"><section><section><section powered-by="gulangu"><section><section><p><img src="image/20201014/7ed41861a62f0702c8e33e514b320bd0_3.jpg" /></p></section></section></section></section><section><section powered-by="gulangu"><section><section><p><img src="image/20201014/1de86fbf08917eb130e818394d545dbb_4.png" /></p></section></section></section></section></section></section></section></section></section><section powered-by="gulangu"><section><section><p><br /></p><p>总部位于德克萨斯州的爱尔康公司表示，PowerVision正在开发基于液体的人工晶状体植入物，该植入物是利用眼睛的自然调节反应来传输植入眼睛囊袋中的人工晶状体。虽然大多数老花眼矫正人工晶状体采用多焦点设计，可在不同焦点之间分配光线，但PowerVision突破性的基于液体的设计创造了一种连续可变的单焦点晶状体，利用眼睛肌肉的自然收缩。该技术使患者能够主动聚焦于物体，就像天然晶状体在年轻人眼中一样。</p><p><br /></p><p><video width="100%" height="580" controls="controls"><source src="http://mpvideo.qpic.cn/tjg_3084203512_50000_ce71735a4d2a48b19fb774afb8003401.f10002.mp4?dis_k=a992459bf7833a7c7226bd95c0fb0c9b&dis_t=1602657166" type="video/mp4"></source></video></p><p><br /></p></section></section></section><section powered-by="gulangu"><section><section><p><span>“我们很高兴正式加入爱尔康及其在眼科领域推出新创新的开创性历史。我们期待在未来几年将这种创新的IOL技术引入眼科护理提供商和客户，“PowerVision prez＆CEO Barry Cheskin在一份声明中表示。</span><br /></p><p><br /></p><p>爱尔康表示，新收购的IOL设备的商业可用性将在人工晶状体的重大额外开发和临床试验后确定。</p><p><br /></p><p>“作为白内障手术的行业领导者，我们迫切希望加快这种潜在突破性的适应性镜片技术的发展。通过治疗白内障和恢复自然，连续的视力范围，这种人工晶状体可能是渴望独立眼镜的白内障手术患者的首选IOL。”爱尔康全球业务和创新prez Michael Onuscheck 在新闻稿中说。</p><p><br /></p></section></section></section><section powered-by="gulangu"><section><section><p><img src="image/20201014/675577ee6606c5cd7f36a3f93f8ab139_5.jpg" /></p></section></section></section><section powered-by="gulangu"><section><section><p><br /></p><p>据了解到，去年12月，爱尔康收购了Tear Film Innovations，收购金额未公开。</p><p><br /></p></section></section></section></section><section data-id="1658"><section><section><section data-id="1658"><section><section><section data-id="1658"><section><section><section data-id="1658"><section><section><p><span><strong>相关阅读</strong></span></p></section><p><p><img src="image/20201014/ec237188ae1e9c03eb4d9814f31b18ab_6.gif" /></p></p><p><br /></p><p><span>突破！FDA 通过首款完全自主人工智能诊断系统，可取代眼科医生</span><br /></p><p><br /></p><p><span>看不见？有我在——一项帮助糖尿病、白内障和失明人群的高科技</span><br /></p><p><br /></p><p><span>【高研值】眼科疾病辅助诊断技术现状及行业代表调研</span><br /></p><p><br /></p><p><span>『大开眼界』眼科手术显微镜的前世今生！</span><br /></p></section></section></section></section></section></section></section></section></section></section></section><p><br /></p><p><span><strong><span>点击阅读原文即可访问官方网站！</span></strong></span></p>
|
|
发表于 2020-10-14 14:32:47